Table 2

Parameter	n(%)
Response to ¹³¹I-rituximab RIT
CR on ¹⁸F-FDG-PET-CT CRu PR on ¹⁸F-FDG-PET-CT PD	24(77%) 2(7%) 4(13%) 1(3%)
Toxicity
Atypical infection Neutropenia <1x109/L Thrombocytopenia <50x109/L Hypothyroidism Myelodysplasia	0(0%) 4(13%) 1(3%) 4(13%) 1(3%)
PFS (months)	median 71, range 6-152
OS (months)	Not reached after a median follow up of 65 months, range 9-152

Table 2: Response to treatment, toxicity, survival. CR – complete remission; CRu – unconfirmed complete remission; PR – partial response; 18F-FDG-PET-CT – Fluorine-18-fluorodeoxyglucose positron emission tomography combined with computerized tomography; PD – progressive disease; PFS – progression-free survival; OS – overall survival.